2-3). Anticytokine therapy in autoimmune diseases

Internal Medicine

Volumn 38, Issue 2, 1999, Pages 178-182

  Nishimoto, Norihiro ^a,b   Kishimoto, Tadamitsu ^b   Yoshizaki, Kazuyuki ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Autoimmune disease; Interleukin 6 (IL 6); Rheumatoid arthritis

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR;

AUTOIMMUNE DISEASE; CONFERENCE PAPER; CYTOKINE PRODUCTION; HYPERGAMMAGLOBULINEMIA; IMMUNE RESPONSE; PATHOGENESIS; PLASMACYTOSIS; PLEIOTROPY; RHEUMATOID ARTHRITIS; THROMBOCYTOSIS;

EID: 0033047195     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.38.178     Document Type: Article

References (32)

1. Smilek DE, Lock CB, McDevitt HO. Antigen recognition and peptide-mediated immunotherapy in autoimmune disease, Immunol Rev 118: 37-71, 1990.
2. Aichele P, Bachmann MF, Hengartner H, Zinkernagel RM. Immunopathology or organ-specific autoimmunity as a consequence of virus infection. Immunol Rev 152: 21-45, 1996.
3. Muraguchi A, Kishimoto T, et al. T cell-replacing factor (TRF)-induced IgG secretion in human B blastoid cell line and demonstration of acceptors for TRF. J Immunol 127: 412-416, 1981.
4. Yoshizaki K, Nakagawa T, Kaieda T, Muraguchi A, Yamamura Y, Kishimoto T. Induction of proliferation and Igs-production in human B leukemic cells by anti-immunoglobulins and T cell factors. J Immunol, 128: 1296-1301, 1982.
5. Hirano T, Yasukawa K, Harada H, et al. Complementary DNA tor a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324: 73-76, 1986.
6. Kishimoto T. The biology of interleukin-6. Blood 74: 1-10, 1989.
7. Noma T, Mizuta T, Rosen A, Hirano T, Kishimoto T, Honjo T. Enhancement of the interleukin-2 receptor expression on T cells by multiple B-lymphotropic lymphokines. Immunol Lett 15: 249-253, 1987.
8. Okada M, Kitahara M, Kishimoto S, Matsuda T, Hirano T, Kishimoto T. IL-6/BSF-2 functions as killer helper factor in the in vitro induction of cytotoxic Tcells. J Immunol 141: 1543-1549, 1988.
9. Ikebuchi K, Wong GG, Clark SC, Ihle JN, Hirai Y, Ogawa M. Interleukin-6 enchancement of interleukin-3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci USA 84: 9035-9039, 1987.
10. Koike K, Nakahata T, Takagi M, et al. Synergism of BSF2/interleukin-6 and interleukin-3 on development of multipotential hemopoietic progenitors in serum free culture. J Exp Med 168: 879-890, 1988.
11. Nicola NA, Metcalf D, Matsumoto M, Johnson GR. Purification of a factor inducing differentiation in murine myelomonocytic leukemia cells. Identification as granulocyte colony-stimulating factor. J Biol Chem 258: 9017-9023, 1983.
12. Ishibashi T, Kimura H, Shikama Y, et al. Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood 74: 1241-1244, 1989.
13. 2/B cell-stimulatory factor type 2 shares identity with monocyte-derived hepatocyte stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 84: 7251-7255, 1987.
14. Castell JV, Gomez-Lechon MJ, David M, Hirano T, Kishimoto T, Heinrich PC. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett 232: 347-350, 1988.
15. 2) regulates β-fibrinogen and albumin mRNA levels in Fao-9 cell. FEBS Lett 221: 18-22, 1987.
16. Ulich TR, del Castillo J, Guo KZ. In vivo hematologic effects of recombinant interleukin-6 on hematopoiesis and circulating numbers of RBCs and WBCs. Blood 73: 108-110, 1989.
17. Horii Y, Muraguchi A, Iwano M, et al. Involvement of interleukin-6 in mesangial proliferative of glomerulonephritis. J Immunol 143: 3949-3955, 1989.
18. Yoshizaki K, Nishimoto N, Matsumoto K, et al. Interleukin-6 and expression of its receptor on the epidermal keratinocytes. Cytokine 2: 381-387, 1990.
19. Tamura R, Udagawa N, Takahashi N, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci USA 90: 11924-11928, 1993.
20. Suematsu S, Matsuda T, Aozasa K, et al. IgG1 plasmacytosis in interleukin-6 transgenic mice. Proc Natl Acad Sci USA 86: 7547-7551, 1989.
21. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 9: 822-830, 1956.
22. Keller AR, Hochholzer L, Castlemen B. Hyalin-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 29: 670-683, 1972.
23. Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castlemanis disease. Blood 74: 1360-1367, 1989.
24. Yoshizaki K, Kuritani T, Kishimoto T. Interleukin-6 in autoimmune disorders. Seminars in Immunol 4: 155-166, 1992.
25. Nishimoto N, Suematsu S, Kishimoto T. Plasma cell dyscrasias. Adv Immunol 64: 219-281, 1997.
26. Beck JT, Hsu SM, Wijdense J, et al. Brief report: alleviation of systemic manifestations of Castlemanis disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 330: 602-605, 1994.
27. Wendung D, Racadot E, Wijenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 20: 259-262, 1993.
28. Klein B, Wijdenes J, Zhang XG, et al. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 78: 1198-1204, 1991.
29. Sato K, Tsuchiya M, Saldanha J, et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res 53: 851-856, 1993.
30. Nishimoto N, Ogata A,Shima Y, et al. Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gpl 30. J Exp Med 179: 1343-1347, 1994.
31. Mihara M, Kotoh M, Oda Y, et al. Anti-IL-6 receptor antibody suppress the onset of collagen arthritis in monkeys. Arthritis Rheum 40: S133, 1997 (Abstract).
32. Firestein GS, Zvaifler NJ. Anticytokine therapy in rheumatoid arthritis. N Engl J Med 337: 195-197, 1997 (editorial; comment).